LAG3 and melanoma: The results of a clinical trial using Relatlimab (LAG-3 inhibitor) and Nivolumab for neoadjuvant therapy in thirty patients with stage III resectable melanoma or single-metastatic stage IV melanoma showed that 57% of patients had complete remission and 70% had a partial response.